Document is current
Any future updates will be listed below
-
Authors
Jeong, Hejin https://orcid.org/0009-0001-7903-0792
Shaia, Jacqueline K.
Kaelber, David C.
Talcott, Katherine E.
Singh, Rishi P. https://orcid.org/0000-0001-5859-8162
-
Funding
Funding for this research was provided by:
Regeneron Pharmaceuticals
Elsevier Foundation
reports personal fees from Alimera, Abbvie, Apellis, Astellas, Eyepoint, Genentech, Outlook, Regeneron, and Zeiss, and research fees from Regeneron and Zeiss.
Research to Prevent Blindness (P30EY025585)
- License Information
-
More Information
Article History
Received: 12 February 2025
Revised: 18 June 2025
Accepted: 20 June 2025
First Online: 16 July 2025
Competing interests
: JKS: Impact Education—Regeneron Pharmaceuticals, Inc.; Elsevier. RPS: personal fees from Apellis, Iveric Bio, Eyepoint, Regenxbio, Genentech, Bausch and Lomb, Zeiss, Alcon, and Regeneron, and research grants from Janssen. KET: personal fees from Alimera, Abbvie, Apellis, Astellas, Eyepoint, Genentech, Outlook, Regeneron, and Zeiss, and research fees from Regeneron and Zeiss. All other authors: no disclosures.
: During the preparation of this work, the authors used ChatGPT in order to improve the readability and language of the manuscript. After using this tool/service, the authors reviewed and edited the content as needed and took full responsibility for the content of the published article.
